| Previous Close | 72.34 |
| Open | 72.32 |
| Bid | 72.57 x 700 |
| Ask | 72.58 x 500 |
| Day's Range | 71.83 - 72.62 |
| 52 Week Range | 63.76 - 82.10 |
| Volume | 2,994,162 |
| Avg. Volume | 8,796,610 |
| Market Cap | 94.67B |
| Beta | 1.08 |
| PE Ratio (TTM) | 7.66 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.84%) |
| Ex-Dividend Date | 2017-09-14 |
| 1y Target Est | N/A |
- Market Realist•3 hours ago
Let’s Explore How Cost Leadership Provides Market Control
Firms with a structural cost advantage can either undercut competitors on price while earning similar margins, or they can charge market-level prices while earning relatively high margins.
- Zacks•3 hours ago
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.
- Motley Fool•15 hours ago
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.
